Related Experiment Video
Updated: May 8, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Heart failure gene therapy: the path to clinical practice
Sven T Pleger1, Henriette Brinks, Julia Ritterhoff
1Center for Molecular and Translational Cardiology, Department of Internal Medicine III, Germany.
Circulation Research
|August 31, 2013
Summary
Gene therapy offers a promising new approach for treating heart failure by targeting genetic causes. Advances in delivery and vector technologies are moving this innovative treatment closer to clinical application.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Biotechnology
Background:
- Conventional drugs often fail to address key pathologies in cardiovascular diseases.
- Heart failure gene therapy involves targeted delivery of DNA and RNA to cardiac cells, particularly cardiomyocytes.
- The goal is to regenerate cardiac function, reverse remodeling, and improve electrical stability and metabolism.
Purpose of the Study:
- To review the current state of heart failure gene therapy.
- To identify key challenges and innovations in the field.
- To discuss the future potential of gene therapy as a clinical treatment for heart failure.
Main Methods:
- Review of existing literature on gene therapy for heart failure.
- Analysis of advancements in delivery technologies and vectors.
- Discussion of challenges in gene expression regulation and therapeutic gene product mechanisms.
Main Results:
- Significant advancements have been made in in vivo gene transfer into the myocardium.
- Heart failure gene therapy has evolved from an experimental tool to a potential clinical option.
- Challenges remain in delivery, vector technology, and regulation of gene expression.
Conclusions:
- Gene therapy holds radical potential for treating cardiovascular diseases and heart failure.
- Overcoming delivery and vector challenges is crucial for clinical success.
- Continued innovation is essential for developing effective and safe heart failure gene therapies.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...